NextBio

Help
Description: Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
Drug Type: Small Molecule; Approved
Pharmacology: Dalfopristin is a streptogramin antibiotic, derived from pristinamycin IIA.
Mechanism of Action: The site of action of dalfopristin is the bacterial ribosome. Dalfopristin
Indication: For the treatment of bacterial infections (usually in combination with quinupristin).
Half Life: The elimination half-life is approximately 0.70 hours.
View Complete Description



Associated Researchers

Help for Associated Researchers

Thought leaders and organizations working on research involving dalfopristin.

View All Author iconAuthors
  • Peter C Appelbaum
  • I Spiliopoulou
  • Po-Ren Hsueh
  • Roland Leclercq
  • Anne Vergison
View All Clinical trial sponsors icon Clinical Trials Sponsors
  • Cubist Pharmaceuticals
  • University of Chicago
  • Oregon Health and Science University
  • Bayer
  • Cadence Pharmaceuticals
View All Affiliations icon Organizations
  • Hershey Medical Center
  • Henry Ford Hospital
  • Université Catholique de Louvain
  • Beth Israel Deaconess Medical Center
  • University of Würzburg

Clinical Trials | 7 trials

Help for Clinical Trials View All

Community

Help for Community
NextBio Users

  • No NextBio users were found for “dalfopristin”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

NextBio Groups

  • No NextBio groups were found for “dalfopristin”.
    Be the first to start a group and share your interests with others within the NextBio community.

© 2010 NextBio